Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line - Role of mitogenic activated protein kinase signaling pathway

FEBS Journal

Volumn 274, Issue 21, 2007, Pages 5714-5726

  Pazos, Yolanda ^a,b   Alvarez, Carlos J P ^c   Camiña, Jesus P ^a,b   Casanueva, Felipe F ^a,b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

c Src; Epidermal growth factor receptor; ERK1 2; Ghrelin; Lysophosphatidic acid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GHRELIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER CELL CULTURE; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GHRELIN; HUMANS; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 35448941943     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.06091.x     Document Type: Article

References (59)

1. Camiña JP (2006) Cell biology of the ghrelin receptor. J Neuroendocrinol 18, 65 76.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656 660.
3. Barreiro ML, Gaytan F, Caminos JE, Pinilla L, Casanueva FF, Aguilar E, Dieguez C Tena-Sempere M (2002) Cellular location and hormonal regulation of ghrelin expression in rat testis. Biol Reprod 67, 1768 1776.
4. Gualillo O, Lago F, Gomez-Reino J, Casanueva FF Dieguez C (2003) Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 552, 105 109.
5. Caminos JE, Nogueiras R, Blanco M, Seoane LM, Bravo S, Alvarez CV, Garcia-Caballero T, Casanueva FF Dieguez C (2003) Cellular distribution and regulation of ghrelin messenger ribonucleic acid in the rat pituitary gland. Endocrinology 144, 5089 5097.
6. van der Lely AJ, Tschop M, Heiman ML Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine Rev 25, 426 457.
7. Caminos JE, Gualillo O, Lago F, Otero M, Blanco M, Gallego R, Garcia-Caballero T, Goldring MB, Casanueva FF, Gomez-Reino JJ et al. (2005) The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted in chondrocytes. Endocrinology 146, 1285 1292.
8. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A et al. (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85, 4908 4911.
9. Tshop M, Smiley DL Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908 913.
10. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194 198.
11. Thompson NM, Gill DAS, Davies R, Loveridge N, Houston PA, Robinson ICAF Wells T (2004) Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145, 234 242.
12. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP Purnell JQ (2002) Plasma ghrelin levels after diet-induced weight loss of gastric bypass surgery. N Engl J Med 346, 1623 1630.
13. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707 709.
14. Shintani M, Ogawa Y, Ebiihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50, 227 232.
15. English PJ, Ghatei MA, Malik IA, Bloom SR Wilding JP (2002) Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87, 2984 2987.
16. Gaytan F, Barreiro ML, Caminos JE, Chopin LK, Herington AC, Morales C, Pinilla L, Paniagua R, Nistal M, Casanueva FF et al. (2004) Expression of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in normal human testis and testicular tumors. J Clin Endocrinol Metab 89, 400 409.
17. Trayhurn P (2005) The biology of obesity. Proc Nutr Soc 64, 31 38.
18. Gardell SE, Dubin AE Chun J (2006) Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12, 65 75.
19. Osborne N Stainier DY (2003) Lipid receptors in cardiovascular development. Annu Rev Physiol 65, 23 43.
20. Tigyi G, Fischer DJ, Sebok A, Marshall F, Dyer DL Miledi R (1996) Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling. J Neurochem 66, 549 558.
21. Bagga S, Price KS, Lin DA, Friend DS, Austen KF Boyce JA (2004) Lysophosphatidic acid accelerates the development of human mast cells. Blood 104, 4080 4087.
22. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M Fukuzawa K (2002) Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. Biol Reprod 67, 1386 1392.
23. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB Korbonits M (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87, 2988 2991.
24. Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, Raimondo F, Cocchi D Solcia E (2002) Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 117, 511 519.
25. Corbetta S, Peracchi M, Cappiello V, Lania A, Lauri E, Vago L, Beck-Peccoz P Spada A (2003) Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 88, 3117 3120.
26. Papotti M, Cassoni P, Volante M, Deghenghi R, Muccioli G Ghigo E (2001) Ghrelin-producing endocrine tumors of the stomach and the intestine. J Clin Endocrinol Metab 86, 5052 5059.
27. Wei W, Wang G, Qi X, Englander EW Greeley GH Jr. (2005) Characterization and regulation of the rat and human ghrelin promoters. Endocrinology 146, 1611 1325.
28. Moolenaar WH, van Meeteren LA Giepmans BNG (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26, 870 881.
29. Mills GB Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3, 582 591.
30. Zhao Y, Usatyuk PV, Cummings R, Saatian B, He D, Watkings T, Morris A, Spannhake EW, Brindley DN Natarajan V (2005) Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J 385, 493 502.
31. Pulinilkunnil T, An D, Ghosh S, Qi D, Kewalramani G, Yuen G, Virk N, Abrahani A Rodrigues B (2005) Lysophosphatidic acid-mediated augmentation of cardiomyocyte lipoprotein lipase involves actin cytoskeleton reorganization. Am J Physiol Heart Circ Physiol 288, H2802 H2810.
32. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RCN Jr. Mills GB (1999) Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5, 3704 3710.
33. Shiono S, Kawamoto K, Yoshida N, Kondo T Inagami T (1993) Neurotransmitter release from lysophosphatidic acid stimulated PC12 cells: involvement of lysophosphatidic acid receptors. Biochem Biophys Res Comun 193, 667 673.
34. Shida D, Kitayama J, Yamguchi H, Hama K, Auki J, Arai H, Yamashita H, Mori K, Sako A, Konishi T et al. (2004) Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res 301, 168 178.
35. Gutkind JS (2000) Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci-STKE doi:10.1126/stke. 2000.40.re1.
36. van Leeuwen FN, Giepmans BNG, van Meeteren LA Moolenaar WH (2003) Lysophosphatidic acid: mitogen and motility factor. Biochem Soc Trans 31, 1209 1212.
37. DeFea KA, Zalevsky J, Thoma MS, Derry O, Mullins RD Bunnet NW (2000) β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK 1/2. J Cell Biol 148, 1267 1281.
38. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL Lefkowitz RJ (2001) Activation and tartgeting of extracellular signal-regulated kinases by β-arrestins scaffolds. Proc Natl Acad Sci USA 98, 2449 2454.
39. Shah BH, Baukal AJ, Shah FB Catt KJ (2005) Mechanisms of ERK1/2 activation in adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. Mol Endocrinol 19, 2535 2548.
40. Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK Lefkowitz RJ (1997) Gβγ subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G-protein-coupled receptor-mediated Ras activation. J Biol Chem 272, 4637 4644.
41. Cooper JA, Gould KL, Cartwright CA Hunter T (1986) Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 231, 1431 1434.
42. Sicheri F, Moarefi I Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602 609.
43. Xu W, Harrison SC Eck MJ (1997) Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595 602.
44. Ayrapetov MK, Wang YH, Lin X, Gu X, Parang K Sun G (2006) Conformational basis for SH2-Tyr(P)527 binding in Src inactivation. J Biol Chem 281, 23776 23784.
45. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C Ullrich A (1999) EGF receptor transactivation by G-protein-coupled receptors requies metalloproteinase cleavage of proHB-EGF. Nature 402, 884 888.
46. Liu Z Armant DR (2004) Lysophosphatidic acid regulates murine blastocyst development by transactivation of receptors for heparin-binding EGF-like growth factor. Exp Cell Res 296, 317 326.
47. Santiskulvong C Rozengurt E (2003) Galardin (GM 6001), a broad spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in Rat-1 cells. Exp Cell Res 290, 437 446.
48. Keates S, Keates AC, Nath S, Peek RM Jr. Kelly CP (2005) Transactivation of the epidermal growth factor receptor by cag+ Helicobacater pylori induces upregulation of the early growth response gene Egr-1 in gastric epithelial cells. Gut 54, 1363 1369.
49. Voisin L, Foisy S, Giasson E, Lambert C, Moreau P Meloche S (2002) EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 283, C446 C455.
50. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH Schlessinger J (2001) Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signalling cascade. J Biol Chem 276, 20130 20135.
51. i-coupled receptors. Biochem Biophys Res Commun 244, 5 10.
52. Pages C, Daviaud D, An S, Krief S, Lafonta M, Valet P Saulnier-Blache JB (2001) Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-dependent control of 3T3F442A preadipocyte proliferation and spreading. J Biol Chem 276, 11599 11605.
53. Ferry G, Tellier E, Try A, Gres S, Naime I, Simon MF, Rodriguez M, Boucher J, Tack I, Gesta S et al. (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. J Biol Chem 278, 18162 18169.
54. Yildiz BO, Suchard MA, Wong M-L, McCann SM Licinio J (2004) Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 101, 10434 10439.
55. Gualillo O, Caminos JE, Blanco M, García-Caballero T, Kojima M, Kangawa K, Diéguez C Casanueva FF (2001) Ghrelin, a novel placental-derived hormone. Endocrinology 142, 788 794.
56. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E Nakano H (2003) Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 192, 161 169.
57. Fonsatti E, Jekunen AP, Kairemo KJA, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M Maio M (2000) Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6, 2037 2043.
58. Camiña JP, Casabiell X Casanueva FF (1999) Inositol 1,4,5-trisphosphate-independent Ca(2+) mobilization triggered by a lipid factor isolated from vitreous body. J Biol Chem 274, 28134 28141.
59. Grynkiewicz G, Poenie M Tsien RY (1985) A new generation of calcium indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440 3450.